Fabry disease in mice is associated with age-dependent susceptibility to vascular thrombosis

被引:60
作者
Eitzman, DT
Bodary, PF
Shen, YC
Khairallah, CG
Wild, SR
Abe, A
Shaffer-Hartman, J
Shayman, JA
机构
[1] Univ Michigan, Med Ctr, Div Cardiol, Ann Arbor, MI 49109 USA
[2] Univ Michigan, Med Ctr, Dept Internal Med, Div Nephrol, Ann Arbor, MI 48109 USA
来源
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2003年 / 14卷 / 02期
关键词
D O I
10.1097/01.ASN.0000043901.45141.D4
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Fabry disease is an X-linked lysosomal storage disorder due to deficiency of a-galactosidase A (GLA) activity that results in the widespread accumulation of neutral glycosphingolipids. Renal failure, neuropathy, premature myocardial infarction, and stroke occur in patients with this condition primarily due to deposition of glycosphingolipids in vascular endothelial cells. The clinical consequences of Fabry disease suggest that vascular thrombosis may play a prominent role in the pathogenesis of this disease; however, the vasculopathy associated with Fabry disease has not been extensively studied. To determine if mice genetically deficient in Gla are susceptible to vascular thrombosis, a photochemical carotid injury model was used to induce occlusive thrombosis. In this model, Gla-/0 mice displayed a progressive age-dependent shortening of the time to occlusive thrombosis after vascular injury that correlated with progressive accumulation of globotriasylceramide (Gb3) in the arterial wall. Bone marrow transplantation from Gla-/0 to Gla+/0 mice and from Gla+/0 to Gla-/0 mice did not change the thrombotic phenotype of the host. These studies reveal a potent vascular prothrombotic phenotype in Gla-deficient mice and suggest that antithrombotic therapies as well as therapies designed to reduce the vascular accumulation of Gb3 may have beneficial effects on thrombotic complications in patients with Fabry disease.
引用
收藏
页码:298 / 302
页数:5
相关论文
共 22 条
[11]   MECHANISMS LEADING TO MYOCARDIAL-INFARCTION - INSIGHTS FROM STUDIES OF VASCULAR BIOLOGY [J].
FUSTER, V .
CIRCULATION, 1994, 90 (04) :2126-2146
[12]  
GREWAL RP, 1994, J NEUROL, V241, P153
[13]   Fabry disease:: Preclinical studies demonstrate the effectiveness of α-galactosidase A replacement in enzyme-deficient mice [J].
Ioannou, YA ;
Zeidner, KM ;
Gordon, RE ;
Desnick, RJ .
AMERICAN JOURNAL OF HUMAN GENETICS, 2001, 68 (01) :14-25
[14]   Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice [J].
Jung, SC ;
Han, IP ;
Limaye, A ;
Xu, R ;
Gelderman, MP ;
Zerfas, P ;
Tirumalai, K ;
Murray, GJ ;
During, MJ ;
Brady, RO ;
Qasba, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (05) :2676-2681
[15]   HEMOLYTIC-UREMIC SYNDROME - BASIC SCIENCE [J].
MOAKE, JL .
LANCET, 1994, 343 (8894) :393-397
[16]   Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease - Reversal by enzyme replacement therapy [J].
Moore, DF ;
Scott, LTC ;
Gladwin, MT ;
Altarescu, G ;
Kaneski, C ;
Suzuki, K ;
Pease-Fye, M ;
Ferri, R ;
Brady, RO ;
Herscovitch, P ;
Schiffmann, R .
CIRCULATION, 2001, 104 (13) :1506-1512
[17]   Verotoxin-1-induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress [J].
Morigi, M ;
Galbusera, M ;
Binda, E ;
Imberti, B ;
Gastoldi, S ;
Remuzzi, A ;
Zoja, C ;
Remuzzi, G .
BLOOD, 2001, 98 (06) :1828-1835
[18]   Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice [J].
Ohshima, T ;
Schiffmann, R ;
Murray, GJ ;
Kopp, J ;
Quirk, JM ;
Stahl, S ;
Chan, CC ;
Zerfas, P ;
Tao-Cheng, JH ;
Ward, JM ;
Brady, RO ;
Kulkarni, AB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (11) :6423-6427
[19]   alpha-Galactosidase A deficient mice: A model of Fabry disease [J].
Ohshima, T ;
Murray, GJ ;
Swaim, WD ;
Longenecker, G ;
Quirk, JM ;
Cardarelli, CO ;
Sugimoto, Y ;
Pastan, I ;
Gottesman, MM ;
Brady, RO ;
Kulkarni, AB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (06) :2540-2544
[20]   Enzyme replacement therapy in Fabry disease - A randomized controlled trial [J].
Schiffmann, R ;
Kopp, JB ;
Austin, HA ;
Sabnis, S ;
Moore, DF ;
Weibel, T ;
Balow, JE ;
Brady, RO .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (21) :2743-2749